WILMINGTON, Del. / Feb 20, 2024 / Business Wire / Phreesia, a leader in patient intake, outreach and activation, is proud to release data from an analysis of its cancer prevention campaigns illustrating the significant impact its platform can have on increasing rates of cancer screenings. By engaging patients at critical moments in their healthcare journey, Phreesia is driving an effort to ensure that cancer is caught early, at a stage when it can be treated with good health outcomes.
The analysis revealed that when patients were shown relevant and accurate cancer prevention information while checking in for a visit with their doctor, they found the information helpful and said they would discuss preventive screenings with their doctor or request appointments.
“We underestimate the lifesaving value of clear communications directly to patients about the importance of cancer screenings,” said Hilary Hatch, PhD, a clinical psychologist and Phreesia’s Chief Clinical Officer. “Our technology reaches patients due for preventive care to ensure they are informed and ready to take an active role in getting timely cancer screenings.”
The results highlight a range of different ways that Phreesia's platform helps to increase rates of necessary cancer screenings, which in turn, improves outcomes.
"We believe that engaging patients with high-quality and relevant information about their health results in better health outcomes," said David Linetsky, SVP, Life Sciences, at Phreesia. “The life sciences companies, advocacy groups and nonprofit organizations we work with recognize that educating patients about cancer prevention at the point of care saves lives, and we are incredibly proud to use our platform to enable this type of critical education.”
Cancer is the second-most common cause of death in the U.S., killing about 1,670 people every day, yet cancer screening rates dropped considerably during the COVID-19 pandemic. Phreesia uses its digital intake platform to share vital information about necessary cancer screenings with patients, and recently published data on the positive impact of its cancer-prevention efforts for breast, colorectal, cervical and lung cancer, among others.
For more information on Phreesia, visit www.phreesia.com.
About Phreesia
Phreesia is the trusted leader in patient activation, giving providers, health plans, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 120 million patient visits in 2022–more than 1 in 10 visits across the U.S.–scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit www.phreesia.com.
Last Trade: | US$25.16 |
Daily Change: | 1.32 5.54 |
Daily Volume: | 704,277 |
Market Cap: | US$1.460B |
December 09, 2024 October 28, 2024 October 01, 2024 September 04, 2024 July 30, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB